Stock Track | Rhythm Pharmaceuticals Soars 12.79% Intraday on Better-Than-Expected Q1 Results Driven by IMCIVREE Launch

Stock Track05-05

Rhythm Pharmaceuticals Inc. (RYTM) saw its stock price soar 12.79% during intraday trading on Tuesday.

The significant move higher follows the company's release of its first quarter 2026 financial results, which exceeded analyst expectations. Rhythm Pharmaceuticals reported Q1 product revenue of $60.1 million, representing 84% year-over-year growth and beating the consensus estimate of $55.776 million. The revenue growth was primarily driven by the successful launch of IMCIVREE for acquired hypothalamic obesity in the U.S., with continued uptake for Bardet-Biedl syndrome.

The company also reported a Q1 EPS of $(0.83), which beat the analyst consensus estimate of $(0.84). Wall Street sentiment remains bullish on the stock, with 15 of 16 brokerages rating it "buy" or higher and a median 12-month price target of $140.00.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173386892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-05 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173386892","market":"sg","top_or_hot":-1,"title":"Stock Track | Rhythm Pharmaceuticals Soars 12.79% Intraday on Better-Than-Expected Q1 Results Driven by IMCIVREE Launch","media":"Stock Track","content":"<p>Rhythm Pharmaceuticals Inc. (RYTM) saw its stock price soar 12.79% during intraday trading on Tuesday.</p><p>The significant move higher follows the company's release of its first quarter 2026 financial results, which exceeded analyst expectations. Rhythm Pharmaceuticals reported Q1 product revenue of $60.1 million, representing 84% year-over-year growth and beating the consensus estimate of $55.776 million. The revenue growth was primarily driven by the successful launch of IMCIVREE for acquired hypothalamic obesity in the U.S., with continued uptake for Bardet-Biedl syndrome.</p><p>The company also reported a Q1 EPS of $(0.83), which beat the analyst consensus estimate of $(0.84). Wall Street sentiment remains bullish on the stock, with 15 of 16 brokerages rating it \"buy\" or higher and a median 12-month price target of $140.00.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Rhythm Pharmaceuticals Soars 12.79% Intraday on Better-Than-Expected Q1 Results Driven by IMCIVREE Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Rhythm Pharmaceuticals Soars 12.79% Intraday on Better-Than-Expected Q1 Results Driven by IMCIVREE Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-05 21:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Rhythm Pharmaceuticals Inc. (RYTM) saw its stock price soar 12.79% during intraday trading on Tuesday.</p><p>The significant move higher follows the company's release of its first quarter 2026 financial results, which exceeded analyst expectations. Rhythm Pharmaceuticals reported Q1 product revenue of $60.1 million, representing 84% year-over-year growth and beating the consensus estimate of $55.776 million. The revenue growth was primarily driven by the successful launch of IMCIVREE for acquired hypothalamic obesity in the U.S., with continued uptake for Bardet-Biedl syndrome.</p><p>The company also reported a Q1 EPS of $(0.83), which beat the analyst consensus estimate of $(0.84). Wall Street sentiment remains bullish on the stock, with 15 of 16 brokerages rating it \"buy\" or higher and a median 12-month price target of $140.00.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1173386892","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173386892","pubTimestamp":1777989107,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Rhythm Pharmaceuticals Inc. (RYTM) saw its stock price soar 12.79% during intraday trading on Tuesday.The significant move higher follows the company's release of its first quarter 2026 financial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc."},"translate_title":"个股追踪|IMCIVREE上市带动Q1业绩好于预期Rhythm制药盘中大涨12.79%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":1},"content_text":"Rhythm Pharmaceuticals Inc. (RYTM) saw its stock price soar 12.79% during intraday trading on Tuesday.The significant move higher follows the company's release of its first quarter 2026 financial results, which exceeded analyst expectations. Rhythm Pharmaceuticals reported Q1 product revenue of $60.1 million, representing 84% year-over-year growth and beating the consensus estimate of $55.776 million. The revenue growth was primarily driven by the successful launch of IMCIVREE for acquired hypothalamic obesity in the U.S., with continued uptake for Bardet-Biedl syndrome.The company also reported a Q1 EPS of $(0.83), which beat the analyst consensus estimate of $(0.84). Wall Street sentiment remains bullish on the stock, with 15 of 16 brokerages rating it \"buy\" or higher and a median 12-month price target of $140.00.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173386892","isCrawlerRequest":true}